(NASDAQ: BCRX) Biocryst Pharmaceuticals's forecast annual revenue growth rate of 9.62% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 85.29%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.87%.
Biocryst Pharmaceuticals's revenue in 2025 is $557,506,000.On average, 4 Wall Street analysts forecast BCRX's revenue for 2025 to be $130,555,813,030, with the lowest BCRX revenue forecast at $128,826,068,687, and the highest BCRX revenue forecast at $132,484,981,782. On average, 4 Wall Street analysts forecast BCRX's revenue for 2026 to be $138,050,392,222, with the lowest BCRX revenue forecast at $129,346,671,353, and the highest BCRX revenue forecast at $144,526,017,646.
In 2027, BCRX is forecast to generate $154,171,861,405 in revenue, with the lowest revenue forecast at $141,920,905,110 and the highest revenue forecast at $164,835,819,249.